ArchiMed completed the acquisition of a majority stake in Zyto Group and 42 life sciences.

ArchiMed, a private equity firm, completed the acquisition of a majority stake in medical products companies Zyto Group and 42 life sciences. Financial terms were not disclosed. “Our internal expertise – a majority of ArchiMed team members have science backgrounds and many have operational experience in medical or pathology labs – was key to understanding the potential of Zyto’s complex, industry-leading products. With our backing, these companies have the resources for further product innovation and for rapid international expansion. Our aim is to bring new precision diagnostics to rare diseases such as lymphoma and leukemia," Vincent Guillaumot, ArchiMed Managing Partner.